Controlled Substances & PMP

Prescription Monitoring

Prescription Drug Monitoring Programs (PDMP) / Prescription Monitoring Programs (PMP) are jurisdictionally operated electronic databases which, collect, maintain, and disseminate controlled substance prescription information specific to each jurisdiction’s laws and regulations. PDMP / PMPs are critical decision support tools that state officials, healthcare professionals, and law enforcement officers use to address prescription dug abuse, misuse, and diversion. PDMP and PMP are used interchangeably throughout this website as well as others.



Model Prescription Monitoring Program (PMP) Act of 2021

PMP Spotlights

This section features recent PMP press releases. The intent is to highlight a few programs at a time and is not meant to be a comprehensive list of all the PMPs in the news. If you would like to suggest a particular state / jurisdiction's recent PMP press release, please contact us.


Amid rising opioid overdose rates, State Senator Mattie Hunter (D-Chicago) proposes a new law to increase regulations for the prescription monitoring program (PMP). Senate Bill 1842 allows the PMP to send automatic reports to prescribers and dispensers when medication shopping is detected from five identifications of a prescriber or pharmacy in a six month period.

Press release dated 08/23/2021: [Click Here]


Governor Parson signs SB 63: Creating Statewide Prescription Drug Monitoring Program in Missouri.

Press release dated 06/07/2021: [Click Here]


Saint Louis County PDMP Enables Additional Enhancements for Heathcare Providers. The PDMP monitors the prescribing and dispensing of schedule II-IV controlled substances to assist in the identification and prevention of prescription drug misuse. The goals of this program are to improve controlled substance prescribing, inform clinical practice, and reduce medication misuse and overdose. The system sends Clinical Alerts to assist healthcare providers in identifying patients potentially at risk for overdose or addiction (substance use disorders).

Press release dated 10/20/20: [Click Here]


The New Jersey Prescription Monitoring Program (NJPMP), in partnership with the New Jersey Department of Human Services, announces $1.2 Million in funding obtained from the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) to implement NJPMP integration with electronic health records and pharmacy management systems across the state.

Press Release dated 8/31/20: [Click Here]


The Delaware Office of Controlled Substances (OCS) is pleased to announce a partnership with Appriss Health to provide interoperability services for all prescribers and pharmacists in Delaware. This service will enable providers to quickly and efficiently access PMP Aware and Narxcare data within their EHR, EMR, or pharmacy dispensing software through the PDMP Gateway® while minimizing interruptions to workflow and patient care. The project is funded by a grant from the Centers for Disease Control awarded to the Delaware Division of Public Health.

Press release dated 6/24/20: [Click Here]


U.S. Drug Enforcement Administration, Office of Diversion Control

CDC’s Response to the Opioid Epidemic

U.S. Department of Justice

Bureau of Justice Assistance (BJA)

NABP PMP Interconnect




PMix Architecture and RxCheck

Substance Abuse and Mental Health Services Administration (SAMSHA)